Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
<p>Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Global Journal of Cancer Therapy - Peertechz Publications,
2021-02-13.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Wees de eerste die reageert!